Balversa
by Johnson & Johnson
Balversa is a targeted oral therapy for FGFR-positive urothelial cancer available through the Johnson & Johnson Patient Assistance Program.
Balversa (erdafitinib) is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor approved for adults with locally advanced or metastatic urothelial cancer with susceptible FGFR3 or FGFR2 genetic alterations whose disease progressed during or after at least one line of prior platinum-containing chemotherapy. Patients must be tested for FGFR alterations using an FDA-approved companion diagnostic before starting Balversa. It works by blocking FGFR signaling that drives tumor cell growth. Balversa is taken once daily as an oral tablet, with dose adjustments based on serum phosphate levels.
Patient assistance programs
Johnson & Johnson Patient Assistance Program (J&J withMe)
Manufacturer PAP- Eligibility
- Uninsured or underinsured adults with a valid Balversa prescription from a licensed U.S. oncologist who meet income requirements.
- Income limit
- Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
- Insurance
- Uninsured or underinsured
- How to apply
- Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to J&J withMe on your behalf.
- Phone
- 1-800-652-6227
Need help applying?
ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.
See If You Qualify — Free